Co-Dergocrine Mesylate
Co-Dergocrine Mesylate is used to treat symptoms of mild to moderate dementia in elderly. In some countries , it has been used in the treatment of hypertension, migrain, and in peripheral vascular disease.
Primary Characteristics
It is of Synthetic origin and belongs to Ergot Alkaloid.
It is classified in Ergot Derivative pharmacological group. It is also classified under Psychotherapeutic Drugs .
Molecular Weight: 659.8 · Solubility in Water: null · Solubility in Alcohol: null · Non-proprietary name: Co-Dergocrine Mesylate.
Pharmacokinetics
Absorption: Co-Dergocrine Mesylate has an oral bioavailability is 12.5% (±12.5%).
Elimination: plasma half-life is 2 - 5 hr, renal excretion is 2%.
Advertisement
Indications
Co-Dergocrine Mesylate is primarily indicated in conditions like Cerebral insufficiency, Dementia, Dizziness, Headache, Impaired memory, Migraine, Vascular headaches.
Contraindications
Co-Dergocrine Mesylate is contraindicated in conditions like Hypersensitivity.
Dosage
Co-Dergocrine Mesylate's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 0.3 mg | 0.3 mg | Every 12h | IM | For one week. Followed by oral therapy |
| 1.75 mg | 1.75 mg | Every 8h | PO | For atleast 3 months (For Once a day dosage 4.5mg before breakfast) |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
None recorded.
Side Effects
Co-Dergocrine Mesylate is known to cause more or less tolerable side effects which are usually transient. These include GI upset, Nasal stiffiness, Nausea.
Warnings / Precautions
Available Brands
Storage Conditions
Drug Classification
- 1.24.5 — Psychostimulants, nootropics, and neurotonics